The Lancet Gastroenterology & Hepatology
Издатель: Elsevier · ISSN 2468-1253 · 37 статей
- Robotic pancreatoduodenectomy comes of age: the questions that remain
- Robotic versus open pancreatoduodenectomy: a systematic review and individual patient data meta-analysis
- Thyroid hormone receptor-β agonist simedeutirom (HSK31679) for Chinese patients with metabolic dysfunction-associated steatohepatitis: a 52-week, multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
- THR-β agonism in MASH: expanding the evidence to Asia
- Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD
- Baveno VIII: what's new?
- Defining molecular remission in inflammatory bowel disease: lessons from oncology
- Adjuvant chemoradiotherapy or completion total mesorectal excision after local excision of rectal cancer
- Adjuvant chemoradiotherapy or completion total mesorectal excision after local excision of rectal cancer – Authors’ reply
- Lessons from the TRIPLET-HCC trial
- Lessons from the TRIPLET-HCC trial – Authors’ reply
- The implementation gap in aspirin chemoprevention for Lynch syndrome
- Combination therapy for MASH
- Validation of Rome V for irritable bowel syndrome
- Validation of Rome V for irritable bowel syndrome – Authors’ reply
- Tackling the global liver disease syndemic through primary care in the Asia-Pacific region
- Incidence of inflammatory bowel disease in Jakarta, Indonesia, 2021–24
- Correction to Lancet Gastroenterol Hepatol 2025; 10: 537–49
- Research in Brief
- Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial
- On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
- ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial
- Germline multigene panel testing for colorectal cancer: a systematic review and meta-analysis
- Pathophysiology of irritable bowel syndrome
- The trajectory of inflammatory bowel disease in east and southeast Asia: transitioning from acceleration in incidence to compounding prevalence
- Global, regional, and national burden of gallbladder and biliary diseases in 204 countries and territories, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study
- Guinea-Bissau HepB birth-dose vaccine trial: still unethical
- Lessons from the European LiverScreen and Chinese LiverHealth projects
- Decompensation unmasks renal susceptibility in cirrhosis